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Objectives: Determine the persistence, clinic and economic impact of Etanercept 
(ETN) y Adalimumab (ADA) reduced dose in Rheumatoid Arthritis (RA), Psoriatic 
Arthropathy (PA) and Ankylosing Spondylitis (AS) Patients with at least 1 year in 
Clinical Remission MethOds: Observational, retrospective cohort of patients in off-
label program receiving ETN or ADA at reduced dose for at least 6 months (Jan2010 
to Dec2014). Inclusion Criteria: patients treated with ETN or ADA at standard dose 
that achieve and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during at 
least 1 year were selected to reduce their standard dose.We collected age, sex, indi-
cation, persistence of ETN or ADA at reduced dose during the study period. In these 
patients, we simulated the cost of treatment with ETN or ADA as if they had received 
ETN or ADA at standard dose during their ETN or ADA at reduced dose respec-
tive periods. Economic impact was assessed using Enbrel® and Humira® Spanish 
official prices. Results: From Jan2010 to Dec2014, 144 patients (51% women; age 
51±9 years; 75 RA, 37 PA, 32 AS) received ETN or ADA at reduced dose for at least 0.5 
years. 80 (56%) patients received ETN reduced dose and 64 (44%) patients received 
ADA reduced dose. Patients with ETN reduced dose presented a persistence of 
2,71±1,37years (AR 2,64±1,54, AP 2,56±0,80 y EA 3,04±1,31) and with ADA reduced 
dose presented a persistence of 2,07±0,96years (AR 2,37±0,92, AP 1,86±0,73y EA 
1,74±0,81). Total cost of this low dose strategy throughout the observation period 
were 1.485.510€ . If these patients had been treated with ETN or ADA standard dose, 
the total cost of therapy would have been 2.971.020€ . The implementation of the 
optimized therapy of ETN or ADA saved 1.485.510€ . cOnclusiOns: Reducing the 
dosage of ETN and ADA in selected patients could make treatment more cost-effec-
tive and allow physicians to treat more patients with a fixed budget.
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Objectives: The aim of this study was to explore the treatment protocol of Systemic 
Juvenile Idiopathic Arthritis (SJIA) in Turkey and to assess the impact of pricing and 
reimbursement policies on the treatment budget of SJIA. MethOds: Delphi panel 
method was used in the study. First, a group of rheumatologists answered the Delphi 
panel questionnaire, designed to explore the type and frequency of resources used 
in treatment of SJIA. This was followed by a consensus-building meeting. Budget 
impact was determined by using the Social Security Institution’s related guide-
lines Results: Treatment of SJIA starts with NSAIDs, followed by glucocorticoids 
and DMARDS. Then approximately 40% of the patients, who has not answered the 
agents stated above, continue treatment with biologic agents including anti-TNF 
agents (etanercept, infliksimab, adalimumab), IL-1 (canakinumab) or IL-6 inhibitors 
(tocilizumab). cOnclusiOns: Biologic agents had the largest share in total treatment 
costs mainly because of their relatively higher prices. Some biologics are imported 
from abroad through Turkish Pharma Association as they are not included in posi-
tive list by the Social Security Institution (SSI) yet, adding to the high cost dilemma.
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Objectives: To analyze the changes in pharmacotherapy and their impact on 
costs for 2 years period for patients with rheumatoid arthritis (RA). MethOds: 
The study is retrospective regarding to the cost for the last 1 year (May 2013 - May 
2014) and prospective regarding to the costs for the current therapy (May 2014-May 
2015). It is conducted in all clinical centers that periodically examine chronic RA 
patients. Bottom-up approach was applied using data from the patients’ records 
during their last visit to specialists in the clinical centers. Results: A total 11.83% 
men and 88.17% women with RA were observed. In the age group 51-60 years are 
32.26% of all patients and in the age group over 60 years are 24.73%. 31 patients 
were transferred to biological therapy during their last examination. The average 
RA pharmacotherapy monthly costs for biological drugs, NSAIDs, disease-modifying 
drugs, p.o. corticosteroids and parenteral corticosteroids for 1 year and from now 
on are: 763.60 (SD 296.90) vs. 890.62 (SD 134.58), 5.10 (SD 4.74) vs. 3.54 (SD 3.43), 5.37 
(SD 5.53) vs. 3.40 (SD 4.01), 3.30 (SD 1.40) vs. 2.59 (SD 1.15), 0.37 (SD 0.70) vs. 1.21 
(SD 2.27), respectively. The costs increased significantly (p> 0.05) when biological 
medicines and parenteral corticosteroids started to be prescribed, and decreased for 
the other therapeutic groups mostly due to price revision or new generics entrance. 
Combination of disease-modifying rheumatoid agents (DMRA) and biological treat-
ment is prescribed to 35.5% of the 31 patients on biological therapy. cOnclusiOns: 
The variations in the pharmacotherapy costs are due to wide differences in therapy 
regimes and significantly high costs for biological therapy. Biological treatment 
consumes a significant financial resources but it is an inevitable option especially 
for patients with no effect from disease-modifying drugs.
Objectives: The aim of this study was to assess the disease activity as well as 
indirect costs associated to absenteeism and presenteeism generated by patients 
with ankylosing spondylitis (AS) in a Polish population. MethOds: On-line ques-
tionnaire survey was performed to obtain data on disease activity and the quality 
of life. We used Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) with 
additional questions about days missed from work (absenteeism) and decrease of 
on-the-job productivity (presenteeism). BASDAI score was obtained using on-line 
calculator. Total indirect costs were estimated with the Human Capital Approach 
using gross domestic product (GDP) per capita equaled € 10,774 and gross value 
added (GVA) per worker equaled € 25,838. Costs were expressed in 2014 euro. The 
Spearman’s correlation was used to present the association between the disease 
activity and the indirect costs. Results: Total 66 questionnaires were obtained. 
Patients reported mostly the problems with general discomfort and morning stiff-
ness represented by 8 points on BASDAI scale, followed by tiredness and neck pain 
represented by 7 points and other pain represented by 5 points. Almost 30% of 
patients reported that morning stiffness lasts longer than two hours. The mean 
BASDAI score was 5.87 (SD: 1.81). Of all patients 62% were working. Mean number 
of days missed from work was 41 a year (SD: 94) generating indirect cost of € 1,197 
(SD: € 2,776) calculated using GDP per capita and € 2,871 (SD: € 6,657) calculated 
using GVA per worker. Mean decrease of on-the-job productivity was 49% (SD: 24%) 
which was responsible for € 5,287 (SD: € 2,552) and € 12,678 (SD: € 6,120) of indirect 
costs, calculated using GDP per capita and GVA per worker, respectively. Disease 
activity was significantly correlated with indirect costs generated by absenteeism 
(0.271) and presenteeism (0.715). cOnclusiOns: AS is a disease that generates 
huge economic burden. Study revealed that indirect costs are associated with 
the disease activity.
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Objectives: To provide an estimation of expected lifetime numbers, risks, and bur-
den of fractures for 50-year old Chinese women. MethOds: A discrete event simu-
lation model was developed to simulate the lifetime fractures of 50-year old Chinese 
women at the average risk of osteoporotic fractures. Main events in the model 
included hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture. Input fracture risks were calculated with the FRAX® tool and the declin-
ing exponential approximation of life expectancy (DEALE) approach. Simulations 
of 50-year old Chinese women without fracture risks were also carried out to 
determine the burden of fractures. Results: For a 50-year old Chinese woman 
at the average risk of fractures, there are 0.135 (95% CI: 0.134-0.137) hip fractures, 
0.120 (95% CI: 0.119-0.122) vertebral fractures, 0.095 (95% CI: 0.094-0.096) wrist frac-
tures, 0.079 (95% CI: 0.078-0.080) humerus fractures, and 0.407 (95% CI: 0.404-0.410) 
other fractures expected for the rest of her life. The residual lifetime risks of any 
fracture, hip fracture, vertebral fracture, wrist fracture, humerus fracture, and other 
fracture for a 50-year old Chinese woman are 37.36%, 11.77%, 10.47%, 8.61%, 7.30%, 
and 27.80%, respectively. The fracture-attributable excess quality-adjusted life year 
(QALY) loss and lifetime costs are estimated at 0.11 QALYs (95% CI: 0.00-0.22 QALYs) 
and US$714.61 (95% CI: US$709.20-720.02), totaling to a net monetary benefit loss 
of US$1,104.43 (95% CI: US$904.09-1,304.78). cOnclusiOns: Chinese women at 
the age of 50 years old are at a high risk of any osteoporotic fracture. The expected 
economic and quality of life burden attributable to fractures among Chinese women 
is substantial.
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Objectives: No adequate data are available about the epidemiology of spinal 
fusion surgery and its economic impact. The objective of this analysis was to 
assess the epidemiologic and economic burden of arthrodesis from a large popula-
tion based-study. MethOds: Lombardy Region includes around 9.9 million indi-
viduals. The study population was identified through a data warehouse (DENALI), 
which matches with a probabilistic linkage demographic, clinical and economic 
data of different Healthcare Administrative databases. The study population was 
made by all subjects who, during the period January 2001–December 2010, under-
went a spinal fusion surgery identified by one of the following codes ICD9-CM: 
81.04 81.05, 81.06, 81.07 and 81.08. The first procedure was used as index event. We 
estimated the incidence of first spinal fusion surgery, the population and surgery 
characteristics and the healthcare costs from the National Health Service’s per-
spective. Results: During the study period, 17,772 (53.2% female) spinal fusion 
surgeries were detected. The results showed an increasing patients’ average age 
during the time period considered. The incidence rate of interventions increased 
from 12.6 to 19.1 per 100,000 person-year in the observational period between 
2001 and 2006. During the last 4 years of observation, the incidence was above 
20.0 per 100,000 person-year. The average hospital length of stay reported for the 
index event was 17.1 days in the 2001 and decreased until 11.0 days in the 2004. 
The average cost of the spinal fusion surgery increased during the observational 
period, from € 4.381 up to € 9,388. cOnclusiOns: The study showed an increas-
ing incidence of spinal fusion surgery and costs from 2001 to 2010 in the Italian 
Lombardy Region. These results can be used to better understand the epidemio-
logical and economic burden of these types of interventions, and help to optimize 
the resources available considering the different surgical procedures available 
today.
